ClinicalTrials.gg
Not yet recruitingNCT07939750Updated Nov 16, 2026

Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes

A Phase 4 interventional study of Sotagliflozin and Empagliflozin (oral) in Type 2 Diabetes Mellitus (DM), sponsored by Allied Hospital Faisalabad. Not yet recruiting at 1 site in Pakistan. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Allied Hospital Faisalabad · Phase 4, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. sotagliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
15th of 28
140 · median 208
Started
2026
with 2 others
Phase 4
2 of 28
2 open now
Registered
28th of 28
by date
Lead sponsor
1 of 28
Allied Hospital Faisalabad

Among the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2, this one is the 15th largest by planned enrollment, is one of 3 that started in 2026, is one of 2 in phase 4, and was the 28th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sotagliflozin

sotagliflozin: first FDA approval 2023 (INPEFA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The goal of this randomized controlled trial is to compare two medicines added to metformin for blood sugar control in adults with type 2 diabetes whose HbA1c remains between 7.0% and 10.0% despite a stable dose of metformin. The main question it aims to answer is: Does adding sotagliflozin (a dual SGLT1/SGLT2 inhibitor) lower HbA1c more than adding empagliflozin (a selective SGLT2 inhibitor) after 24 weeks? Participants will continue their usual metformin dose and will be randomly assigned to take either sotagliflozin 200 mg or empagliflozin 10 mg once daily for 24 weeks. They will be reviewed at 4, 12 and 24 weeks for adherence, side effects and adverse events, and HbA1c will be measured at baseline and at 24 weeks.

Read the detailed description

Pakistan has one of the highest adult diabetes prevalences in the world, and many patients fail to reach HbA1c targets on metformin monotherapy and require a second agent. SGLT2 inhibitors such as empagliflozin are established second-line agents. Sotagliflozin additionally inhibits intestinal SGLT1, blunting post-prandial glucose absorption and enhancing incretin release, which may provide additional glucose lowering. No head-to-head randomized comparison of these two combinations has been performed in Pakistan.

This is a single-centre, open-label, parallel-group randomized controlled trial with blinded outcome assessment, conducted at the Department of Medicine and Diabetic Clinic/Medicine OPD, Allied Hospital-I, Faisalabad Medical University. 140 patients (70 per group) will be enrolled by consecutive sampling and randomized 1:1. Sample size was calculated for 95% confidence, 80% power, SD of HbA1c change 1%, and a minimal clinically important difference of 0.5%, inflated by 10% for loss to follow-up. HbA1c will be measured by a standardized laboratory method at baseline and 24 weeks, with laboratory staff blinded to group allocation. Data will be analysed in SPSS; mean change in HbA1c will be compared using the independent-samples t-test (p ≤ 0.05 significant), with stratification for age, gender, BMI, duration of diabetes and baseline HbA1c.

03

Conditions studied

  • Type 2 Diabetes Mellitus (DM)
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 30 to 65 years, male or female
  • Diagnosed type 2 diabetes mellitus (ADA criteria)
  • Inadequately controlled on metformin: stable dose ≥1500 mg/day (or maximum tolerated dose) for at least 8 weeks, with ≥7.0% and ≤10.0% at screening
  • Willing to provide written and attend scheduled follow-up

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus or secondary diabetes
  • Use of any SGLT inhibitor, GLP-1 receptor agonist, DPP-4 inhibitor or sulfonylurea within the previous 8 weeks
  • \<45 mL/min/1.73 m², or significant hepatic impairment
  • Pregnancy, lactation, or women of not using
  • Haemoglobinopathies
  • Known to any study drug, or any condition making the patient unsuitable for the trial
  • Recurrent genital/urinary tract infections or history of Fournier's gangrene
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Metformin + Sotagliflozin (Group A)

    Existing stable dose of metformin plus sotagliflozin 200 mg orally once daily for 24 weeks.

    Drug: Sotagliflozin · Drug: Metformin

  • Active comparator
    Metformin + Empagliflozin (Group B)

    Existing stable dose of metformin plus empagliflozin 10 mg orally once daily for 24 weeks.

    Drug: Empagliflozin (oral) · Drug: Metformin

Interventions

  • 200 mg tablet orally once daily for 24 weeks

  • 10 mg tablet orally once daily for 24 weeks

  • continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated)

06

What researchers measure

Primary outcomes

  1. Change in HbA1c From Baseline to Week 24

    Glycated haemoglobin (%) measured by a standardized laboratory method. Change calculated as baseline HbA1c minus week-24 HbA1c for each participant; a between-group difference ≥0.5% is considered clinically meaningful.

    Time frame: Baseline and 24 weeks

Secondary outcomes

  1. Number of Participants With Adverse Events

    Adverse events including genital/urinary tract infections, hypoglycaemia and gastrointestinal symptoms, recorded at follow-up visits.

    Time frame: Up to 24 weeks (assessed at weeks 4, 12 and 24)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared; aggregate results will be published in a peer-reviewed journal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 12 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Jan 31, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939750
Lead sponsor
Allied Hospital Faisalabad
Responsible party
Sheraz Ali (Post-graduate Resident, FCPS Internal Medicine, Allied Hospital Faisalabad) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Sheraz Ali
Contact
sheraz.mirza10@gmail.com
+923330360744
Sheraz Ali
principal investigator · Faisalabad Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotagliflozin

Start the discussion